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ABSTRACT
Objectives: The objectives of the study were to develop and evaluate a pediatric hospital formulary in a tertiary care hospital erode and to provide 
updated information about the use of medicines to physicians, pharmacists, and other health-care professionals in the hospital for appropriate use 
of the drugs.
Methods: The prospective developmental study was carried out in a tertiary care hospital, Erode, Tamil Nadu, for a period of 6 months. A survey was 
conducted using a validated questionnaire for the identification of the need and content of pediatric formulary among physicians in the hospital. The 
pediatric formulary was developed, and the quality was evaluated using a validated questionnaire form. The content of the formulary was framed 
based on the opinion of physicians.
Conclusion: The formulary was handy, user-friendly and saves the precious time of busy physician. It may also promote the safe and effective use of 
medicines thereby minimizing drug-related problems in the pediatric population.
Keywords: Formulary, Pediatrics, Clinical practice.
INTRODUCTION
Even though pediatric patients comprise a wide proportion of the patient 
population, but concern about their medication safety has been neglected 
for a long time. Drug prescribing for pediatric patients offers special 
challenge [1]. They are the most vulnerable group of the population 
suffering from frequent but usually non-serious illness. Children are 
more often exposed to unlicensed and off-label medication use, which 
potentially forms a greater risk for adverse drug reactions (ADRs). 
Pediatric practitioners should be aware of the fact that growth and 
development are an important signal of a child’s general well-being [2].
Pharmacokinetic and pharmacodynamic changes in pediatrics
There is the high importance of clinical pharmacokinetics in the 
optimization of drug therapy. Safety and efficacy of drugs may vary 
among different groups of pediatric patients it can either be effective, 
ineffective or toxic, so it is essential to be aware of the variability in 
drug disposition if children are to receive rational and appropriate 
drug therapy. Lack of data on important pharmacokinetic (absorption, 
distribution, metabolism, and excretion) and pharmacodynamic 
differences (medicine targets, such as receptors, transporters, and 
channels are certainly also subjected to developmental processes [as 
are metabolizing enzymes]) has led to several terrible situations in 
pediatric care. Inability to obtain true informed consent is the primary 
issue and the second issue is inherent to children; the rapid growth and 
changes occur in children. Hence, drug studies must be performed on 
children at each stage of their development to determine appropriate 
usage. Highly critical aspects in child treatment are pharmacokinetic 
parameters, method of drug administration, dose, and dosage forms.
Consequences of the lack of studies of medicine development in 
children and authorization of pediatric medicines
Medicines of major clinical importance, even essential medicines, are 
not readily tested and not officially approved for use, especially in 
Problem arise during the use of medication in children
Wrong dosage causes short-term toxicity or treatment failure. Health 
care providers forced to administering the crushed tablets, dissolving 
tablets in solvents or administering the powder contained inside 
the capsule due to lack of non-availability of appropriate pediatric 
formulations.
The suitable formulations are not available for administration to 
neonates, infants, and young children. Adult formulations should be 
diluted or administered in miniscule volumes over a period of time. This 
leads to administration errors, especially in circumstances that require 
urgent action (as in emergency units, premature units, and NICU).
Complications in pediatric populations
Most of the medicines have not been adequately tested and/or 
formulated and authorized for use inappropriate pediatric age groups 
therefore in pediatric patients many medicines are prescribed on 
an unlicensed and off-label manner. The lack of reliable data in the 
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the very young. This led Harry Shirkey in 1963 to state that, children 
constitute therapeutic orphans. Among the 340 medicines in the WHO 
model List of essential medicines 2007 [3] those that have relevance 
for  pediatric  populations  should  be  the  top  priority  for 
documenting pediatric experiences, wherever these medicines 
are  being  used.  However,  all  drugs  that  are  tested  in  adult 
population probably cannot be met therapeutic needs in children if 
medicines  are  not  tested  and  labeled  for  pediatric  use.  Once  a 
medicine becomes available on the market for adults, it is possible to 
use  it  in  children  in  an  off-label  way.  Even  though  unlicensed  and 
off-label medicines for children became a practice for decades; this
 does not provide the same quality, safety, and efficacy of medicines 
as  adults  [4].  Therefore,  it  is  not  surprising  that  pediatric  patients 
are exposed to a  rate of  potentially  dangerous medication errors 3 
times higher than that for adult patients [1].
pediatric population is associated with specific problems including: 
Less availability of safety data due to the shortage of clinical trials in 
the pediatric population; under- or over-dosing in some age groups 
due to the lack of pharmacokinetics data; maturation, growth, and 
development of the pediatric population susceptible to drug-induced 
growth and development disorders as well as to delayed ADRs not 
findable in adults. The spectrum of adverse reactions in children may 
differ due to the variability in pharmacodynamics and pharmacokinetics 
in children from adults [5]. Furthermore, children are more often 
exposed to unlicensed and off-label medication use, which potentially 
forms a greater risk for ADRs [6,7]. More knowledge on occurrence 
and content of ADRs in the pediatric setting is necessary, thereby can 
prevent those events.
Pre-marketing trials are do not manage to establish a safety profile 
but it can able to provide information about the benefits of drugs [8]. 
To promote reasonable warning signs spontaneous reporting of ADRs 
plays a key role. The World Health Organization defines ADRs as 
unintended and harmful responses to a drug and which occurs with 
doses normally used in humans for prophylaxis, diagnosis or treatment 
of a disease or modifying a physiological function. It is a condition which 
rarely is associated with a significant impact on the health system. The 
occurrence of ADRs is natural to the use of medicines, and in some 
cases, the hospital admission is needed. In children, ADRs risk factors 
are relatively unknown. Pharmacokinetics and pharmacodynamics in 
children differ from adults, and therefore the range of adverse reactions 
in children may differ as well [5]. Furthermore, children are more often 
exposed to off-label and unlicensed medication use, which potentially 
forms a greater risk for ADRs [6,7]. Because part of these events may be 
preventable, more knowledge on occurrence and content of ADRs in the 
pediatric setting is necessary.
Limitations of available hospital formulary
There is a lack of availability and reliability of pediatric drug dosing 
guidelines in present hospital formulary. The lack of adequate and 
evidence-based dosing recommendations for pediatric patients reflects 
the lack of drug studies in this population.
Necessity of pediatric formulary
Medication and its management is central to the quality of care received 
by most hospitalized children and is dependent on an evidence-based 
formulary that ensures safe, effective, and rational use of medicines. It 
is the fundamental responsibility of drug and therapeutics committees 
to evaluate medicines for addition to the hospital formulary. For 
pediatric hospitals, committee decisions also have a strong impact on 
access to medicines to treat rare conditions, transition to adult services, 
outpatient medication supply, and hospital drug budgets. In India, few 
hospitals are having hospital formulary of their own. Among those 
hospitals, only a few hospitals are having their own pediatric drug 
formulary. Therefore, the presence of the pediatric formulary might 
help in the pediatric prescribing pattern.
Pediatric formulary should be complete, concise, updated, and easy 
to use since it is a tool for health-care professionals mainly medical 
and nursing staffs make use of this tool periodically [9]. Pediatric 
formulary aims to provide prescribers, pharmacists, and other health-
care professionals with sound updated information on the use of 
medicines for treating children. Many fields of pediatric practice have 
suffered from inadequate information on effective medicines. By 
providing practical information on the use of medicines in children of 
all ages from birth to adolescence pediatric formulary addresses this 
significant knowledge gap. Against emerging evidence, best practice 
guidelines, and crucially advice from a group of clinical expert’s 
information in pediatric formulary have been updated. This is essential 
because licensed indications frequently do not cover the clinical needs 
of children; in some cases, products for use in children need to be 
specially manufactured or imported. For unlicensed interventions, to 
establish the clinical needs with respect to the evidence and experience 
of their safety and efficacy careful consideration has been given; clinical 
literature has been invaluable in this process.
Therefore, the presence of the pediatric formulary might help in the 
pediatric prescribing pattern, and the main objective of developing 
this pediatric formulary is to set standards for best practice, promoting 
high quality and evidence-based prescribing thereby minimizing the 
variation in the level of treatment provided to the patients.
METHODS
The prospective developmental study was conducted in tertiary care 
hospital in South India for 6 months. No pediatric formulary was 
available in the hospital. Hence, the drug information center which 
belongs to the pharmacy practice initiated the concept of preparing 
pediatric formulary.
The study received clearance from the Ethical Committee after 
submitting the proposal with study title, duration, objectives, and a 
brief methodology about the work to be carried. The protocols and 
guidelines approved by Pharmacy and Therapeutic committee of the 
hospital were collected.
The drug list was collected from hospital pharmacy and categorized 
the drugs to be included in the pediatric drug formulary which was 
verified by the pediatrician. Appropriate Drug Information resources 
such as LEXICOMP and MICROMEDEX were selected and the drugs in 
the pediatric department as per hospital formulary drug list. Layout of 
drug monograph was designed. Monograph for all drugs in the list from 
standard primary, secondary, and tertiary drug information resources 
was prepared. The developed pediatric formulary was given to the 
physicians in Government Headquarters Hospital Erode. The feedback 
form for evaluating the formulary was prepared. The developed 
pediatric formulary was implemented and later evaluated among 58 
doctors using suitably designed feedback questionnaire.
Two types of questionnaires were framed one for the selection of 
information to be included in each monograph, and other for the 
evaluation of developed pediatric formulary was evaluated using 
suitable feedback questionnaire. Based on the information from the 
questionnaire pediatric formulary was developed.
RESULTS
About 50–75% of drugs that are used in the pediatric population have 
not been studied adequately to provide appropriate labeling information. 
Due to the prescriber’s reluctance to use a medication for an off-label 
use pediatric patients may also be deprived of potentially effective 
medication [10]. Off-label use in pediatrics affects both seriously ill 
inpatients and the millions of children treated outside the hospital for 
various types of illness. The problem of off-label use of drugs in pediatrics 
is international and affects pediatric patients in the United States, Europe, 
Asia, Africa, and South America [11-14]. Appropriate drug prescribing 
is quite challenging since DRPs have become a priority, due to the 
complexity of today’s drug therapy [15-17]. Various studies have shown 
that DRPs in the pediatric population are of major concern [15,18,19].
Of 58 doctors, 50 (86.2%) doctors were satisfied with the developed 
formulary for about 29 (50%) doctors formulary was very useful in 
their clinical practice. For third question (Table 1), 50 (86.2%) of them 
had preferred very useful and 8 (13.8%) of them had preferred useful. 
For fourth question 50 (86.2%) of them had preferred very helpful, 
5 (8.62%) had preferred helpful, and 3 (5.172%) of them had preferred 
not helpful. For the fifth question 50 (86.2%) of them had preferred to 
great extend option, 5 (8.62%) had answered moderately option, and 
3 (5.172 %) had preferred the option little.
For the sixth question, 29 (50%) had preferred very useful. For the 
seventh question, 40 (68.96%) of them had preferred the option 
frequently, 10 (17.24%) of them had preferred occasionally, 5 (8.62%) 
of them had preferred the option rarely, and 3 (5.172%) of them had 
preferred never. For the eighth question, 58 (100%) of them had 
preferred yes. For the ninth question, 50 (86.2%) of them had preferred 
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satisfied and (13.8%) of them had preferred not satisfied. For the tenth 
question, 50 (86.2%) of them had preferred agree and 8 (13.8%) of 
them had preferred disagree.
DISCUSSION
In our study, Table 1 showed the comments for the feedback 
questionnaires by the physicians of Headquarters Hospital Erode. 
For the first question, 29 (50%) doctors had preferred to great extent 
option in the form, 21 (36.206%) had preferred convenient option, 
5 (8.62%) had preferred little option, and 3 (5.172%) had preferred not 
at all option. For second question, 50 (86.2%) of them had preferred 
sufficient, 7 (12.06%) had preferred average, and 1 (1.724%) had 
preferred below average.
ADRs in a pediatric population are an important public health 
problem [20]. Due to the high incidence of drug-induced reactions 
especially in the pediatric population, despite efforts being made 
to reduce the incidence of medication-related adverse events, the 
morbidity, and mortality [21,22].
Unrecognized and/or unresolved DRPs can potentially lead to 
significant drug-related morbidity and/or mortality [23,24]. 
Hospitalizations, long-term care admissions, emergency department 
visits, additional physician office visits, and additional prescriptions are 
certain consequences associated with DRPs [25].
Regarding ADRs among pediatric patients, several studies have been 
done in different parts of the world. It has been found that in every 
year in young children of age group of newborn to 2 years of age, ADRs 
were associated with 243 reported deaths [26]. A study reported 
that ADRs occurred more among infants and antibiotics were more 
commonly implicated. Most of the reactions were of moderate 
severity [26].
CONCLUSION
The necessity of pediatric formulary was supported by 80% of 
physicians at first but after the implementation of formulary 86% was 
highly satisfied with the formulary and appreciated the work that was 
carried out to a great level. The formulary is handy, user-friendly and 
saves the precious time of busy physician. It may also promote the 
safe and effective use of medicines thereby minimizing drug-related 
problems in the pediatric population. The physicians highly appreciated 
the pivotal role played by the clinical pharmacists in providing unbiased 
information and promoting better pharmaceutical care and opined 
that the services of the clinical pharmacist are very much essential to 
optimize their daily practice.
New drugs and treatments are emerging all the time, and without 
evaluation, the formulary may become a collection of older, less 
effective drug. Therefore, the entire formulary should be reviewed 
every 2–3 years.
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Table 1: Response of the doctors based on the need of pediatric formulary
S. no Feedback questionnaire/comment Number of doctors n=58 (%)
1 Whether the order of contents in each monograph is convenient to refer?
To a great extent 29 (50)
Convenient 21 (36.206)
Little 5 (8.62)
Not at all 3 (5.172)
2 The content in each drug monograph is 
Sufficient 50 (86.2)
Average 7 (12.06)
Below average 1 (1.724)
3 Is it useful to get aware of the contraindications, side effects, and ADRs of pediatric drugs 
available in the hospital pharmacy?
Very useful 50 (86.2)
Useful 8 (13.8)
4 Dose prediction
Very helpful 50 (86.2)
Helpful 5 (8.62)
Not helpful 3 (5.172)
5 Whether this formulary promotes the safe and effective use of medicines?
To a great extent 50 (86.2)
Moderately 5 (8.62)
Little 3 (5.172)
6 Will it be useful in your clinical practice?
Very useful 29 (50)
Useful 29 (50)





8 Whether the formulary is handy?
Yes 
No 58 (100)
9 Are you satisfied with the developed formulary?
Satisfied 50 (86.2)
Not satisfied 8 (13.8)
10 Do you feel that a clinical pharmacist is required in your daily practice?
Agree 50 (86.2
Disagree 8 (13.8)
ADRs: Adverse drug reactions
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